ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Co-morbidities"

  • Abstract Number: 260 • 2016 ACR/ARHP Annual Meeting

    Risk of Cardiovascular Disease Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study

    Patompong Ungprasert1, Cynthia S. Crowson2 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN

    Risk of Cardiovascular Disease Among Patients With Sarcoidosis: A Population-Based Retrospective Cohort Study Background/Purpose: Several epidemiologic studies have demonstrated an increased incidence of atherosclerotic cardiovascular…
  • Abstract Number: 2213 • 2016 ACR/ARHP Annual Meeting

    The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches

    Mark Gostine1, Fred Davis1, Bradley Roberts2, Rebecca Risko2, Joseph C Cappelleri3, Andrew Clair4 and Alesia Sadosky5, 1Michigan Pain Consultants, PC, Grand Rapids, MI, 2ProCare Systems, Inc., Grand Rapids, MI, 3Statistics, Pfizer Inc, New London, CT, 4Pfizer, New York, NY, 5Pfizer Inc,, New York, NY

    Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and tenderness making it difficult to manage. Accounting for FM heterogeneity might elicit an improvement in…
  • Abstract Number: 877 • 2016 ACR/ARHP Annual Meeting

    Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis

    Patompong Ungprasert1, Matthew J. Koster2, Kenneth J. Warrington3 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, 3Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN

    Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-analysis Background/Purpose: Several chronic inflammatory disorders, such as rheumatoid arthritis and…
  • Abstract Number: 2292 • 2016 ACR/ARHP Annual Meeting

    Decreased Endothelial and Smooth Muscle Responsiveness in the Vasculature of Gout Patients Compared with Healthy Controls: Relationship Between Flow- and Nitrate-Mediated Dilation, Serum Urate and CRP

    Aaron Garza Romero1, Stuart Katz2, Virginia Pike3, Daisy Bang1, Binita Shah4, Talia Igel1,5, Bruce Cronstein6, Irina Dektiarev2, Jonathan Samuels7, Michael H. Pillinger8 and Svetlana Krasnokutsky Samuels9, 1Medicine/Rheumatology, NYU School of Medicine, New York, NY, 2Medicine/Cardiology, NYU School of Medicine, New York, NY, 3Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 4NYU School of Medicine, Division of Cardiology, New York, NY, 5Monash University School of Medicine, Melbourne, Australia, 6Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 7Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, NY, 8NYU School of Medicine, New York, NY, 9Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY

    Background/Purpose: Gout is an independent risk factor for cardiovascular disease (CVD). Investigators studying the relationship between gout and CVD have focused on acute coronary outcomes,…
  • Abstract Number: 1188 • 2016 ACR/ARHP Annual Meeting

    Major Comorbidities of Idiopathic Inflammatory Myositis: A Population-Based Study Using 10 Years of Follow up from the National Health Insurance in Korea

    Jeong Seok Lee1, Min Jung Kim2, Hee Young Lee3, So Yeon Ahn4, Yeong Wook Song5, Eun Bong Lee6, Eun Young Lee7, Yun Jong Lee8 and Eun Ha Kang9, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 2Division of Rheumatology, Departmenf of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, 3Center for Preventive Medicine and Public health, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, 4Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, 5Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, 6Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of, 7Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 8Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, 9Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of

    Major comorbidities of idiopathic inflammatory myositis: A population-based study using 10 years of follow up from the national health insurance in KoreaJeong Seok Lee1, Min…
  • Abstract Number: 2463 • 2016 ACR/ARHP Annual Meeting

    Association Between High Sodium Intake and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

    Gulsen Ozen1, Ali Ugur Unal2, Simge Saydam3, Murat Sunbul4, Kursat Tigen4, Haner Direskeneli5 and Nevsun Inanc1, 1Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 3Marmara University Faculty of Medicine, Istanbul, Turkey, 4Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, Turkey, 5Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: High sodium intake has been reported to be associated with increased ACPA positivity in smoker RA patients. However, apart from this, the associations with…
  • Abstract Number: 1195 • 2016 ACR/ARHP Annual Meeting

    Risk of Hospitalized Infection Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study

    Patompong Ungprasert1, Cynthia S. Crowson2 and Eric L. Matteson1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN

    Risk of Hospitalized Infection Among Patients With Sarcoidosis: A Population-Based Retrospective Cohort Study Background/Purpose: Increased risk of infection has been observed in several autoimmune disorders. …
  • Abstract Number: 2533 • 2016 ACR/ARHP Annual Meeting

    Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?

    M. Victoria Hernández1, Carlos Sánchez-Piedra2, Jose Inciarte-Mundo1, Fernando Sanchez-Alonso2, Javier Manero3, Rosa Roselló4, Eva Pérez-Pampin5, Carlos Rodriguez-Lozano6, Cesar Diaz-Torné7, Raimon Sanmarti1, Juan J. Gómez-Reino5 and Biobadaser 2.0 Study Group, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 4Rheumatology, H San Jorge, Huesca, Spain, 5Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, 6Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 7Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose:  Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used,…
  • Abstract Number: 826 • 2015 ACR/ARHP Annual Meeting

    Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.

    Len Harty1, Deirdre Fitzgerald2, Michael Henry2, John Ryan3 and Sinead Harney3, 1Cork University Hospital, Cork, Ireland, 2Respiratory, Cork University Hospital, Cork, Ireland, 3Rheumatology, Cork University Hospital, Cork, Ireland

    Background/Purpose: Despite the advent of potent immunosuppressive and vasoactive therapies it is not clear that longevity of patients with systemic sclerosis (SSc) has improved. Therefore…
  • Abstract Number: 912 • 2015 ACR/ARHP Annual Meeting

    Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis

    Ängla Mantel1, Marie Holmqvist1, Tomas Jernberg2, Solveig Wållberg-Jonsson3 and Johan Askling4,5, 1Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Section of Cardiology, Department of medicine, Karolinska University Hospital, Stockholm, Sweden, 3Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, 4Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 5Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Suboptimal use of secondary preventive pharmacotherapies after acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) has been suggested to contribute to an…
  • Abstract Number: 1290 • 2015 ACR/ARHP Annual Meeting

    Burden of Rheumatoid Arthritis in the US Elderly Population: Comorbidities, Healthcare Resource Utilization, and Cost

    Chieh-I Chen1, Li Wang2, Wenhui Wei3, Huseyin Yuce4 and Kristine Phillips5, 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Director, Analytic Research, STATinMED Research, Plano, TX, 3Sanofi-Aventis, Bridgewater, NJ, 4New York City College of Technology (CUNY), New York, NJ, 5Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease resulting in significant healthcare resource utilization (HRCU) and cost. Data on elderly RA patients are generally…
  • Abstract Number: 1419 • 2015 ACR/ARHP Annual Meeting

    Increasing Comorbidity Is Associated with Worsening Physical Function during Intermediate-Term Follow-up of Primary Total Knee Arthroplasty

    Maren Hilton1, Terence Gioe2 and Jasvinder A. Singh3, 1Arthritis and Rheumatology Consultants, Edina, MN, 2Department of Orthopaedic Surgery, Minneapolis VA Medical Center, Minneapolis, MN, 3University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Total knee arthroplasty (TKA) is associated with significant gains in function and pain improvement.  However, decline in function has been noted in patients who…
  • Abstract Number: 1535 • 2015 ACR/ARHP Annual Meeting

    The Clinical Impact of Overweight in Rheumatoid Arthritis Patients: Comparison Between Korean and Other Countries within the Comora Study

    Kichul Shin1, Eun Young Ahn2, Hyun Mi Kwon2, In Ah Choi3, Yeonsoo Baik4 and Yeong Wook Song2, 1Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 3Division of Rheumatology, Department of internal medicine, Chungbook National University Hospital, Cheongju-si, South Korea, 4Division of Rheumatology, Department of internal medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea

    Background/Purpose: Obesity has recently been spotlighted as an important comorbidity in rheumatoid arthritis (RA); not only associated with disease severity but also its development. Despite…
  • Abstract Number: 1698 • 2015 ACR/ARHP Annual Meeting

    High Prevalence of Traditional Cardiovascular Risk Factors in an Ankylosing Spondylitis Cohort

    Gillian Fitzgerald1, Dara J Lundon2, Phil Gallagher3, Claire Sheehy4, Catherine Sullivan5, Carmel Silke6, Frances Stafford7, Killian O Rourke8, Muhammad Haroon9, Ronan Mullan10, Oliver FitzGerald11 and Finbar (Barry) O'Shea12, 1Rheumatology, St James's Hospital, Dublin 8, Ireland, 2School of Medicine, University College Dublin, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 4University Hospital Waterford, Waterford, Ireland, 5Rheumatology, UCHG Ireland, Galway, Ireland, 6Rheumatology, Sligo University Hospital, Sligo, Ireland, 7Rheumatology, Blackrock Clinic, Co Dublin, Ireland, 8Rheumatology, Midlands Regional Hospital, Tullamore, Co Offaly, Ireland, 9Rheumatology, Kerry General Hospital, Co Kerry, Ireland, 10Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, 11St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin 4, Dublin 4, Ireland, 12Rheumatology Dept, St James's Hospital, Dublin, Ireland

    Background/Purpose: Patients with Ankylosing Spondylitis (AS) have previously been considered an otherwise healthy patient population. However, emerging evidence suggests AS is an independent risk factor…
  • Abstract Number: 2325 • 2015 ACR/ARHP Annual Meeting

    Quantitative Clues to Recognize and Document Comorbid Fibromyalgia in Routine Care of Patients with Other Rheumatic Diagnoses on a 10 Cm Distress Visual Analog Scale Found on 1-Page Physician Rheumetric Checklist

    Kathryn A. Gibson1, Katherine J. Bryant2 and Theodore Pincus3, 1Liverpool Hospital, Liverpool, Australia, 2University of New South Wales, Sydney, Australia, 3Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: A physician global estimate (DOCGL) is commonly used to assess patients with rheumatic diseases. Fibromyalgia (FM) has been reported as a comorbidity in 10-35%…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology